Children with early-onset atopic dermatitis (AD) have an elevated risk for pediatric uveitis, according to a study published ...

Tralokinumab use in patients with head and neck atopic dermatitis was associated with sustained improvements with up to 4 years of treatment.

A research team at Korea University Medical School discovered a gene-regulating substance called 'miR-4497', which was ...

Sanofi SNY and partner Regeneron REGN announced that the FDA approved Dupixent (dupilumab) for the treatment of chronic ...

A panelist discusses how real-world data presented at the 2025 American Academy of Dermatology Annual Meeting (AAD 2025) ...

Dupilumab is associated with a reduced risk of peripheral vascular disease, deep vein thrombosis, hypertension, type 2 diabetes mellitus, obesity, and hyperlipidemia within the first year of treatment ...

Taiwan: A new large-scale cohort study published in JAMA Ophthalmology has revealed that children with early-onset atopic dermatitis (AD) may be at a significantly higher risk of developing pediatric ...

Getty Images Clinical phenotypes of atopic dermatitis can vary greatly based on skin color and can make atopic dermatitis difficult to diagnose. Recognizing the clinical diversity of presentation ...

placebo (95%CI：9.27~74.62). In the higher dose group, 41.7% of patients (5/12) achieved a validated Investigator's Global Assessment for Atopic Dermatitis (vIGA-AD™) score of 0 (clear) or 1 (almost ...

Raj Chovatiya, MD, PhD, MSCI, highlights promising research in atopic dermatitis focused on identifying patient subgroups for targeted treatments and achieving long-term remission. Raj Chovatiya ...

Janus kinase (JAK) inhibitors were associated with more infections, particularly herpes infections, in patients with atopic dermatitis (AD) compared with biologics, in a cohort study. A ...